Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kedrion S.p.A.
The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.
A Phase II trial of the CH24H inhibitor showed a statistically significant benefit in children with the rare epilepsy syndrome Dravet Syndrome, but not in Lennox-Gastaut syndrome (LGS).
Who wants to go public during a once-in-a-century crisis? It seems like quite a few medtechs do.
The LamPORE assay will also be used to test for the winter influenza virus.
- Other Names / Subsidiaries
- Kedrion Biopharma (US)